Amgen, Inc.

Sector: Biological Products Except Diagnostic Substances Region: CA, United States

Exchange/Ticker: Nasdaq: AMGN | Hong Kong Stock Exchange: 4332 | Frankfurt Stock Exchange: AMG

Company Description

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The cpmpany's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Similar to: Cardium Therapeutics, Inc., ALLENEX AB, Retrophin Inc

Featured Media

Amgen Reaffirms 2011 Through 2015 Guidance

Executives

Robert A. Bradway, President and Chief Executive Officer

Robert A. Bradway became Amgen’s president and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012 and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. Prior to joining Amgen, he was a managing director at Morgan Stanley in London where he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990 where he served as head of the firm’s international health care investment banking activities until assuming broader corporate finance management responsibilities. Bradway holds a bachelor’s degree in Biology from Amherst College and an MBA from Harvard University. He is a member of the board of directors of Norfolk Southern Corporation.

Jonathan M. Peacock, EVP and CFO

Jonathan M. Peacock joined Amgen as chief financial officer in September 2010. In this role, he is responsible for finance, investor relations operations and strategy and corporate development. Peacock joined Amgen from Novartis Pharmaceutical AG, where he had served as chief financial and administration officer since 2005. He also was responsible for IT, Purchasing, Strategic Planning and Mergers and Acquisitions at Novartis. In addition, Peacock was responsible for Novartis’ malaria program, a corporate citizenship initiative in conjunction with the major donor organizations, to supply the company’s malaria medicine at cost to countries throughout Africa. Previously, Peacock was a partner at McKinsey and Company, working for the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a Chartered Accountant.

Fabrizio Bonanni, EVP, Operations

Dr. Fabrizio Bonanni is Amgen's executive vice president, Operations, overseeing the company's global production activities as well as site and facilities management. Since joining Amgen in April 1999, Bonanni has served as senior vice president, Manufacturing; senior vice president, Quality and Compliance; and corporate compliance officer. Previously, he was corporate vice president, Regulatory and Clinical Affairs and corporate vice president, Quality System for Baxter International Inc., a company he joined in 1974. At Baxter, Bonanni spent half of his career in international operations, including an eight-year assignment as vice president, Quality and Regulatory Affairs, at the company's European headquarters in Brussels, Belgium. His responsibilities at Baxter included quality and regulatory affairs, manufacturing, microbiology and sterilization engineering, and total quality management, for (bio)pharmaceuticals, blood derivatives, medical devices and in-vitro diagnostics. Bonanni earned his doctorate in chemistry, magna cum laude, from the University of Florence and has done postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is a state-certified chemist and a member of the Ordine dei Chimici of Tuscany. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management, and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. Bonanni is fluent in French and English, in addition to his native Florentine Italian. Bonanni serves on the Board of Trustees for the Museum of Contemporary Art in Los Angeles. He also serves as a Trustee of the Science Technology and Research Trust of Puerto Rico.

Featured Company

Aben Resources Ltd.

Vancouver, BC, CA

Aben Resources (TSX.V: ABN) is a Canadian gold and silver exploration company with a focus on developing properties in the Yukon.… Learn more →